Zentalis to Present Azenosertib Data at ESMO 2026
San Diego, California, USA | July 17, 2026 Zentalis Pharmaceuticals announced that it will present new clinical data for...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
Vaccines, Blood & Biologics
San Diego, California, USA | July 17, 2026 Zentalis Pharmaceuticals announced that it will present new clinical data for...
New Haven, Conn., July 17, 2026 Veradermics announced the presentation of new subgroup analysis data from its Phase 2/3...
Crystal Lake, Ill., July 17, 2026 Aptar Pharma announced the launch of a new integrated system-level framework designed to...
Bridgewater, N.J., July 17, 2026 Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved additional...
Copenhagen, Denmark, July 17, 2026 Evaxion A/S announced that it will present three-year clinical efficacy data from its Phase...
Fort Lauderdale, Fla., July 17, 2026 SS Innovations International announced that its SSi Mantra surgical robotic system will be...
RAMAT-GAN, Israel, July 16, 2026 Galmed Pharmaceuticals Ltd. has announced the breakthrough development of a novel lipid nanoparticle (LNP)...
MENLO PARK, Calif., July 16, 2026 GRAIL, Inc. has announced a strategic collaboration with Priority Health, making the Galleri®...
WASHINGTON, July 16, 2026 Vanda Pharmaceuticals has announced that the Committee for Orphan Medicinal Products (COMP) at the European...
Vancouver, Canada, July 16, 2026 Clearmind Medicine announced positive ex vivo results demonstrating enhanced nasal retention for its intranasal...
